Acucela recently published overall encouraging Phase IIa data for its lead dry AMD compound, emixustat, which is being developed in collaboration with Otsuka. The study proved emixustat modulates the visual cycle and provided proof of concept to continue development. A Phase IIb/III study with emixustat has fully enrolled and data are expected in Q316. Otsuka is co-funding the studies and will co-promote in North America (35-50% profit share to Acucela) or fully commercialise (19-23% royalties).
